Canadian Pharmacogenomics Network for Drug Safety to Study Adverse Drug Reactions in Children and Adults

What this Trial Is About

This research aims to understand how genetic differences affect the way children and adults respond to medications, focusing on those who experience adverse drug reactions (ADRs) compared to those who do not. The study seeks to identify genetic markers linked to ADRs and to develop personalized drug dosing guidelines to help prevent these reactions. It also examines differences in prescription drug use, medical care, hospital services, and vital statistics between participants with and without ADRs. The study collects DNA and plasma samples from patients who have experienced ADRs and from control groups who have taken the same medications without adverse effects. Researchers analyze known and novel genetic variations related to drug metabolism, transport, and targets, using sequencing and genotyping methods. Pharmacokinetic studies assess drug concentrations over time by genotype to understand ADR mechanisms. The study also includes health-economic evaluations to assess the cost-effectiveness of ADR screening programs. Participants include children under 19 years who have taken drugs, their biological parents, and adults for validation purposes. The study involves collecting genetic and clinical information, medical history, and prescription data. Researchers measure the role of genetic and clinical factors in ADRs to develop risk reduction strategies. Participation involves providing samples and information for analysis, with ongoing data collection to support long-term understanding. The study is observational and includes healthy volunteers, with data collected primarily through hospital networks across Canada.

National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children